Cargando…

Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer

PURPOSE: To evaluate the impact on survival of the relative dose intensity (RDI) achieved in patients with early breast cancer receiving anthracycline plus taxane-based chemotherapy in the adjuvant setting. PATIENTS AND METHODS: Patients with early breast cancer diagnosed from January 1999 through D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pérez-Fidalgo, J. A., Bermejo, B., Chirivella, I., Martínez, M. T., González, I., Cejalvo, J. M., Catoira, I., Martínez, P., Contel, E., Lluch, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139588/ https://www.ncbi.nlm.nih.gov/pubmed/24532305 http://dx.doi.org/10.1007/s12094-013-1153-7

Ejemplares similares

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes
por: Lee, Yu Rim, et al.
Publicado: (2011)

Stem Cell Mobilization with G-CSF versus Cyclophosphamide plus G-CSF in Mexican Children
por: Meraz, José Eugenio Vázquez, et al.
Publicado: (2016)

Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
por: Wang, Junbin, et al.
Publicado: (2017)

Corrigendum to “Stem Cell Mobilization with G-CSF versus Cyclophosphamide plus G-CSF in Mexican Children”
por: Vázquez Meraz, José Eugenio, et al.
Publicado: (2016)

Anthracycline dose and liver dysfunction
por: Cannizzaro, R, et al.
Publicado: (1999)

Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane
por: Ahn, Jin-Hee, et al.
Publicado: (2004)

Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer
por: Veronese, Pedro, et al.
Publicado: (2018)

The Impact of Adding Taxanes to Anthracyclines on Women with Breast Cancer Receiving Adjuvant Chemotherapy
por: Hilaj, Erina, et al.
Publicado: (2020)

Sequential vs concurrent adjuvant chemotherapy of anthracycline and taxane for operable breast cancer
por: Chen, Wanjing, et al.
Publicado: (2021)

A MicroRNA Expression Signature In Taxane-anthracycline-based Neoadjuvant Chemotherapy Response
por: Zheng, Yi, et al.
Publicado: (2015)

Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients
por: Kim, Jung Sun, et al.
Publicado: (2014)

IDN 5390: an oral taxane candidate for protracted treatment schedules
por: Pratesi, G, et al.
Publicado: (2003)

Erratum to: Evolving Approaches to Metastatic Breast Cancer Patients Pre-treated with Anthracycline and Taxane
por: Saji, Shigehira
Publicado: (2013)

Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane
por: Zhou, Li-Yan, et al.
Publicado: (2015)

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
por: Schreiber, Anna R., et al.
Publicado: (2021)

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis
por: Pajares, Bella, et al.
Publicado: (2013)

Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline
por: Aomatsu, Naoki, et al.
Publicado: (2014)

Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy
por: Dai, Kun, et al.
Publicado: (2015)

Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment
por: Wang, Zhipeng, et al.
Publicado: (2018)

Clinical Characteristics and Outcome Trends of Adjuvant Anthracycline and Taxane Regimen for Early Stage Breast Cancer
por: Vaid, Ashok K., et al.
Publicado: (2020)

Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF versus G-CSF alone
por: Sung, Anthony D., et al.
Publicado: (2013)

Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology
por: Ntellas, Panagiotis, et al.
Publicado: (2019)

ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers
por: Abdel-Fatah, Tarek M. A., et al.
Publicado: (2019)

Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study
por: Krop, Ian E., et al.
Publicado: (2022)

Incidence of Chemotherapy-Induced Amenorrhea After Adjuvant Chemotherapy With Taxane and Anthracyclines in Young Patients With Breast Cancer
por: Pourali, Leila, et al.
Publicado: (2013)

Optimal radiation dose for patients with one to three lymph node positive breast cancer following breast-conserving surgery and anthracycline plus taxane-based chemotherapy: A retrospective multicenter analysis (KROG 1418)
por: Kim, Haeyoung, et al.
Publicado: (2016)

Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial
por: Tan, Qiu-Wen, et al.
Publicado: (2017)

Survival analysis of bevacizumab plus taxane treatment in luminal metastatic breast cancer
por: Murillo, Serafin Morales, et al.
Publicado: (2021)

Role of Taxane and Anthracycline Combination Regimens in the Management of Advanced Breast Cancer: A Meta-Analysis of Randomized Trials
por: Zheng, Ruinian, et al.
Publicado: (2015)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
por: Di Cosimo, Serena, et al.
Publicado: (2019)

Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
por: Joung, Eun Kyo, et al.
Publicado: (2021)

Tumor Glucose and Fatty Acid Metabolism in the Context of Anthracycline and Taxane-Based (Neo)Adjuvant Chemotherapy in Breast Carcinomas
por: Tőkés, Anna Mária, et al.
Publicado: (2022)

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer
por: Gori, S, et al.
Publicado: (2004)

Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model
por: Vainas, O, et al.
Publicado: (2012)

PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)
por: Liu, Minetta C, et al.
Publicado: (2016)

Chemotherapy Response Assay Test and Prognosis for Breast Cancer Patients Who Have Undergone Anthracycline- and Taxane-Based Chemotherapy
por: Lee, Anbok, et al.
Publicado: (2011)

High Expression of Complement Component C7 Indicates Poor Prognosis of Breast Cancer and Is Insensitive to Taxane-Anthracycline Chemotherapy
por: Zhang, Huikun, et al.
Publicado: (2021)

A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
por: Suo, Jiaojiao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6rtdqv07m3r8en598gqcir4tl3